MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules

Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary.

42 CFR §410.32(a) Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions

CMS Internet-Only Manual, Pub. 100-02, Medicare Policy Manual, Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests, §80.1.1 Certification Changes

This contractor will cover molecular diagnostic tests for use in a beneficiary with an indeterminate or suspicious thyroid nodule when all the following criteria are met:

• The patient:
  • Has not been tested with the same or similar assay for the same clinical indication AND:
    • Has an indeterminate thyroid nodule as defined by Bethesda categories III-IV OR
    • Has a Bethesda category V nodule for which molecular testing may aid in further stratifying the type of malignancy.
• The results of the test will be used to aid in surgical decision making after a consideration of clinical, radiographic and cytologic features.
• The beneficiary is within the population and has the indication for which the test was developed. The laboratory providing the test is responsible for clearly indicating to treating clinicians the population and indication for test use.
• The test demonstrates analytical validity, including both analytical and clinical validation, on a cohort of patients appropriate for its intended use. If the test relies on an algorithm, the algorithm must be validated in a cohort that is not a development cohort for the algorithm.
• The test has demonstrated clinical validity and utility in peer-reviewed, published literature, establishing a clear and significant biological/molecular basis for stratifying patients and subsequently selecting (either positively or negatively) a clinical management decision in a clearly defined population.
• The test successfully completes a technical assessment that ensures the test is reasonable and necessary as described above.
• The performance characteristics of the test have been demonstrated to be as good or better than currently covered services.

NOTE: Next Generation Sequencing (NGS) performed to identify genetic variants in samples classified as malignant is not within the scope of this policy but may fall under other established policies.

Background

Thyroid cancer (TC) is the most common endocrine malignancy, consisting of nearly 3% of all newly diagnosed cancer cases in the United States each year.¹ Greater than 70% of those cases are women, representing the fifth most diagnosed malignancy in females. It is the second most common cancer among Hispanic and Asian/Pacific Islander women in the US, who also have the highest mortality rates.² Differentiated thyroid carcinoma is the most common form, accounting for around 90% of all cases and includes papillary thyroid carcinoma (PTC), follicular carcinoma (FC) and Hurthle cell carcinoma (HTC).^3,4 Medullary thyroid carcinoma (MTC), a rare neuroendocrine tumor that arises from the neural crest-derived parafollicular calcitonin-secreting thyroid C cells, represents 4% of all TC.⁵ Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid tumor and while only around 1-2% of all TC, accounts for the majority of TC death.⁶

The diagnosis of TC in the United States has tripled over the last 25 years.¹ Several studies attribute the significant increase to overdiagnosis of small indolent tumors that would otherwise not cause symptoms or require treatment with a majority of the increase being explained by PTC tumors 2 cm or smaller.^7-11 In fact, recent studies suggest the incidence rate of thyroid cancer stabilized between 2013-2016 and declined between 2016-2018.^12,13 This stabilization followed by decline has been postulated to be a result of changes in practice patterns and reclassification of some cancer types. In 2016, the Endocrine Pathology Society working group reported clinical outcomes and refined the diagnostic criteria for encapsulated follicular variant of papillary thyroid carcinoma (EFVPC) and proposed replacing the term with non-invasive follicular thyroid neoplasm with papillary-like nucleus features (NIFTP) to describe these tumors more accurately.¹⁴ The American Thyroid Association (ATA) recommended this terminology change in 2017.¹⁵ This led to the reclassification of approximately 10-20% of thyroid tumors from malignant to benign.¹⁴ In addition, guidelines for the management of thyroid nodules have become increasingly more conservative regarding size thresholds for nodule biopsy and discourage biopsy for nodules < 1 cm.^16,17 However, some studies have reported a true increase in advanced-stage and larger PTC tumors as well as incidence-based mortality that cannot be explained by overdiagnosis and suggest that lifestyle-related factors such as obesity may be contributory.^10,18 Also, there continue to be disparities in diagnosis and treatment of TC in patients based on race, ethnicity and socioeconomic status with patients from minority backgrounds more likely to present with larger tumors, and distant metastases than white patients.^2,19,20 However, a recent report from Ginzberg et al. suggests that the updated ATA guidelines ameliorated some of these disparities.²¹

TC almost exclusively presents as thyroid nodules, occurring in 7-15% of cases depending on gender, age, radiation exposure, family history and other factors.¹⁶ However, thyroid nodules are very common; most are asymptomatic and benign and do not require monitoring, treatment, or evaluation. In fact, over 60% of the population will have a thyroid nodule by the time they are over the age of 65.¹⁶ Therefore, it is important to distinguish between benign and malignant nodules for patients to receive appropriate treatment and prevent unnecessary surgery.

The malignancy potential of a thyroid nodule is determined through a multimodality manner including physical exam, personal and family history, radiographic assessment, and fine needle aspiration (FNA) biopsy. FNA biopsies are the procedure of choice when evaluating clinically suspicious thyroid nodules and every year more than 500,000 of this minimally invasive procedure are performed.²² The results of FNA biopsies are reported using the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC).²³ This system was established to provide consensus recommendations for diagnostic categories for FNA specimens with a goal of standardizing classification and reporting across health care providers. It includes recommendations on sample adequacy, malignancy risk, report layout and management and has been widely adopted. As shown in Table 1 (reproduced from TBSRTC), the system recognizes six diagnostic categories and provides an estimated cancer risk for each, based on identification of cancer in a subsequent nodule resection.

TABLE 1

A repeat aspiration with ultrasound guidance is recommended for nondiagnostic Bethesda category I samples with excision considered for persistently non-diagnostic or unsatisfactory nodules.²³ Category II almost always results in conservative surveillance as data continue to support a low false-negative rate (<3%). Category VI, malignant, is used whenever features are conclusive for malignancy with additional comments used to subclassify the malignancy. In this case, near-total thyroidectomy or lobectomy is recommended. While this system has been successful in distinguishing benign nodules from malignant, approximately 20-25% of thyroid nodule FNA results are reported as indeterminate or suspicious (Bethesda III-V) and nodules in these categories carry a risk of malignancy from ~10-75%.²³ In addition, intra- and inter-observer variability has been reported leading to differences in classification and the risk of malignancy (ROM) for these categories.^24,25

Despite advances in technique, thyroid surgery is not without adverse effects including general complications such as postoperative fever, infection, hemorrhage, and cardiopulmonary events as well as thyroid-specific complications including vocal cord/fold paralysis and hypoparathyroidism or hypocalcemia. Thyroid-specific complications have been reported in more than 10% of patients and are significantly higher in patients greater than 65 years of age.²⁶ As such, there has been a concerted effort to develop technologies to improve the classification and risk stratification of indeterminate and suspicious thyroid nodules as part of the surgical decision making process.

Molecular Testing

Current clinical guidelines, including the ATA Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer, and The National Comprehensive Cancer Network (NCCN) Thyroid Carcinoma guidelines endorse the use of molecular tests to further risk stratify patients with indeterminate (Bethesda III and IV) thyroid nodule cytology results, as well as their use in identifying cancer types with challenging cytology such as MTC.^16,27 Molecular tests can be broadly grouped into “rule-out” tests designed to identify benign nodules thereby placing the patient on surveillance and avoiding surgery, “rule-in” tests that aim to predict the aggressiveness of malignancy and aid in surgical decision making and “general” tests that can act as both rule-in and rule-out. Most currently offered tests utilize Next Generation Sequencing (NGS) methodologies to either assess characteristic gene expression profiles (GEP) or genomic sequence variant profiles that are known to be associated with malignancy.

First generation Tests

The Afirma gene expression classifier (AGEC) is an early GEP test that was developed as a rule-out.²⁸ The landmark publication in 2012 described the test validated against the gold standard histopathology of known benign or malignant thyroid tissue and classified indeterminate thyroid nodules into benign or suspicious using a proprietary algorithm based on gene expression signatures.²⁸ The algorithm assesses the expression of 142 primary genes plus 25 additional genes that filter out rare neoplasms such as medullary carcinoma and renal carcinoma as the sample is processed through a series of “cassettes.” This prospective study examined 265 of 577 indeterminate nodules from 4812 FNAs (5.5%) collected from 3789 patients at 43 clinical sites over a 19-month period. The AGEC correctly called 78 of 85 malignant samples suspicious for a sensitivity of 92% and 93 of 180 benign samples were called correctly for a specificity of 52%. These percentages were relatively consistent regardless of the sample category. The prevalence of malignancy (POM) was 24% and 25% for Bethesda category III and IV nodules respectively, yielding a negative predictive value (NPV) of 95% and 94% respectively. Because the POM for category V was much higher at 62%, the respective NPV was 85%. These data suggested that the AGEC could rule out malignancy in over 90% of indeterminate category III and IV nodules. Since then, the test has garnered wide acceptance in clinical practice and as described above, the approach has been recommended by professional associations.^16,27

Many follow up reports including multiple meta-analyses on the performance of the AGEC have been published.^29-31 Silaghi et al. summarized 25 studies involving 4,538 indeterminate nodules of 4,424 patients who had been evaluated using the AGEC test from May of 2009 to June of 2018.³⁰ The overall sensitivity and specificity across all studies was 97% and 19% respectively with an NPV of 91% and positive predictive value (PPV) of 39%. However, most of the reports are retrospective from single centers and demonstrate variable test performance among institutions. Some reports indicate variability amongst institutions that differ in POM of indeterminate nodules.^32,33 For example, in a study comparing the AGEC-benign call rate between Memorial Sloan Kettering Cancer Center (MSK), a tertiary referral cancer center with a POM of 30-38%, and Mount Sinai Beth Israel (MSBI) a comprehensive health system with a POM of 10-19%, Marti et al found that the NPV at MSK was 86-92% yet 95-98% at MSBI. Conversely the PPVs of GEC-suspicious results were 57.1% and 13.3% respectively with 86% (18/21) of resected GEC-suspicious nodules at MSBI being ultimately benign on final pathology. This data matched closely to the predicted PPVs and NPVs and highlights the importance of knowing the POM at each institution.³³ Valderrabano et al reported that the low resection rate of GEC-benign nodules makes the false-negative and NPV impossible to calculate and the only reliable metrics of benign call rate (BCR, the proportion of nodules tested with a GEC-benign result) and PPV suggested that the initial cohort study is not representative of the populations to which the AGEC was subsequently applied.³⁴

In 2011, Nikiforov et al. reported on the efficacy of a gene hot spot panel in 967 FNA samples from indeterminate nodules for variants that commonly occur in thyroid cancer such as BRAF p.V600E, KRAS codons 12/13, NRAS and HRAS codon 61 and RET and PAX8 fusions establishing that molecular profiling using FNAs of thyroid nodules can aid in malignancy identification as a rule-in test.³⁵ This report was followed by further clinical validation studies on Bethesda III and IV nodules using ThyroSeq v2 (TSv2), a panel consisting of additional variant hotspots in genes known to be drivers in thyroid carcinogenesis as well those that develop late with expression analysis of an additional eight genes to determine cell type composition. The larger number of variants examined resulted in a higher sensitivity than the original seven gene panel as well as a higher NPV. In a study of 143 FNA samples from patients with Bethesda category IV nodules with known surgical outcomes, the TSv2 test demonstrated a sensitivity and specificity of 90% and 93% respectively with a PPV of 83% and an NPV of 96%.³⁶ Similar results were obtained for category III nodules.³⁷ However, like the AGEC, variability across multiple institutions has been reported.^38-40 For example, in a retrospective analysis of 273 category III and IV nodules from four different institutions, Marcadis et al. reported variation in test performance and diagnoses.³⁸ Although sensitivity was similar to what was originally reported by Nikiforov, the specificity was lower (52% vs. 93%). This led to a range of PPVs from 22%-43% across the institutions which is lower than what was originally reported at 83%. A PPV of 22% was reported by Taye et al. with a PPV of 9% (2/22) and 7% (1/15) across all RAS and NRAS mutations respectively. The authors noted that many genetic alterations, such as those in the RAS family, appeared to be nonspecific for malignancy and positive reports should be interpreted with care.³⁹

Second generation tests

Updated versions of both rule-in and rule-out test types have been developed. The AGEC was replaced by the Afirma Genomic Sequencing Classifier (AGSC) which analyzes the entire RNA transcriptome rather than a subset of genes and includes classifiers to identify samples with BRAF or RET alterations, as well as characteristic MTC, PTC and HTC profiles.⁴¹ These tests use a proprietary algorithm to classify an indeterminate nodule as benign or suspicious. Thyroseq v3 (TSv3) is an expanded version of TSv2 containing variant targets in 112 genes as well as copy number alterations (CNAs) in multiple genomic regions and expression analysis of 19 genes. Results are reported as positive (high probability of cancer/NIFTP) or negative (low probability of cancer/NIFTP).⁴² Positive samples are further classified into high, intermediate and low molecular risk groups based on the variant(s) identified.

Multiple reviews have been performed on these second-generation tests and describe increased performance over their predecessors.^30,43,44 In Lee et al., preliminary pooled studies demonstrated that both assays, AGSC and TSv3, have a high sensitivity (96% and 95% respectively) and high NPV (96% and 92% respectively) demonstrating that either test type can be used to rule out malignancy.⁴³ The AGSC and TSv3 were reported to have a specificity of 53% and 50% with a PPV of 63% and 70% respectively. Although this represents an increase in specificity for the AGSC (12% to 53%) the specificity for TSv3 compared to TSv2 went down (78% to 49.6%). However, the specificity of the tests ranged considerably across multiple studies particularly from single centers suggesting inter-institution variation similar to what was seen in the first-generation tests. Silaghi reported similar results.³⁰ Livhits et al performed a randomized clinical trial across nine sites by using both the AGSC and the TSv3 in practice on a rotating monthly basis.⁴⁵ Of the 346 samples ultimately tested, 189 and 157 were randomized to the AGSC and TSv3 respectively. For the AGSC test, 19 nodule samples were insufficient for testing, 107 (53.2%) were classified as benign and 73 (36.3%) as suspicious. Twelve of the benign samples were surgically resected and histopathologically classified as benign. Fifty-eight of the suspicious samples were resected and revealed NIFTP in 10 (17.2%) and malignancy in 21 (36.2%). The TSv3 test identified 103 (60.2%) negative nodules, 60 (35.1%) positive, and seven insufficient for testing. Eleven negative nodules were resected, and one was found to be a minimally invasive Hurthle cell carcinoma with capsular invasion only that was resected due to growth during the surveillance period. Of the positive nodules, 49 (81.7%) were resected and histopathological results revealed NIFTP in 11 (22.4%) and malignancy in 20 (40.8%). These data demonstrated high sensitivity (97-100%) and reasonably high specificity (80-85%) for both tests and diagnostic surgery was avoided in approximately half of the patients in the study.⁴⁵ However, consistent with similar studies, nodules with benign/negative results were assumed to be benign in the absence of histopathological confirmation. Therefore, to further assess the false negative rates of the AGSC and TSv3, Kim et al. performed a prospective study of a single center in patients surveilled over a median of 34 months (range 12-60).⁴⁶ They reported that of the 217 indeterminate nodules initially reported with negative or benign results 14 (8%) underwent immediate resection and were all confirmed to be benign. Of the 147 that remained on continued surveillance, 15 were resected during the surveillance period. The minimally invasive Hurthle cell carcinoma initially found to be negative by TSv3, remained the only false positive. Of the 133 test positive nodules, 97 underwent immediate resection and 59 were determined to be cancerous and of those that were initially surveilled, 16 ultimately underwent delayed surgery with an additional nine found to be malignant. These data reaffirm the high sensitivity rate previously reported for both assays.⁴⁶

Molecular profiles

The variants identified in a nodule can also predict the risk and/or class of malignancy. For example, nodules with “driver” mutations such as BRAF p.V600E or pathogenic variants in RET have a higher probability of malignancy than those carrying RAS or RAS-like variants.¹⁶ Tumors harboring BRAF p.V600E are generally classic PTC that frequently involve regional lymph nodes with a higher rate of metastasis, and RET mutations are present in all inherited MTCs and 6-10% of apparent sporadic disease.^15,47-50 In contrast, RAS alterations (KRAS/NRAS/HRAS) are the most frequently identified in indeterminate thyroid nodules. However, unlike BRAF p.V600E, the utility of detecting RAS alterations remains uncertain. In a systemic review of 35 studies examining RAS mutations published between 2000 and 2015, Najafian et al. reported a prevalence of RAS mutations in 0-48% of benign nodules and 10-93% of malignant nodules across the studies.⁵¹ In a study of over 1500 patients, Yip et al. reported an indolent clinical course and nearly 100% disease free survival at five years for patients with RAS-positive nodules.⁵⁰ Guan et al. also reported that although RAS variants were the most frequent alterations detected in more than 500 fine needle biopsies, they provided poor value for prediction of TC since most RAS alterations presented in benign nodules and NIFTPs (59% and 13% respectively).⁵² However, the presence of a “second-hit” in another gene such as TERT or TP53 significantly increased the risk of malignancy.

Key decisions that must be made in the care of patients with suspicious thyroid nodules include whether to surgically intervene, the extent of surgery (such as a full vs. partial thyroidectomy), and the selection of therapeutic intervention. Tests designed to rule-out a disease should have high sensitivity and NPV, and those designed to rule-in should have high specificity and PPV with tests that provide both high rule-in and rule-out probabilities being ideal. A high sensitivity and NPV is necessary for rule-out tests on indeterminate nodules that would otherwise be surgically removed. However, a test’s efficacy as a rule-out is based on its NPV which changes based on institution and POM. Rule-in tests with high specificity should only be considered if the results will alter the management of the patient. Knowledge of the disease prevalence in indeterminate thyroid nodules at any institution is critical for clinicians to anticipate the diagnostic performance of a test.

NCCN guidelines state that molecular testing may be useful to allow reclassification of Bethesda III and IV nodules.²⁷ In addition, NCCN acknowledges the challenges of diagnosing MTC and molecular tests may assist in identification as well as provide information to aid in extent of surgery such as a lobectomy vs. total thyroidectomy. However, the guidelines also note that the results of the tests should be interpreted in the context of clinical, radiographic and cytologic features of each patient. The most recent ATA guidelines were published in 2016 and state that molecular testing may be useful after consideration of clinical and sonographic features if such data is expected to alter surgical decision making.¹⁶ They also recommend that if molecular testing is being considered, either rule-out or rule-in, patients should be appropriately counseled regarding the benefits and limitations of these tests and note that the utility of these types of tests is strongly influenced by the prevalence of cancer in the population being tested. The American Association of Endocrine Surgeons (AAES) note that molecular testing is primarily utilized as a preoperative adjunct to refine the cancer risk in cytologically indeterminate thyroid nodules, and that molecular testing is acceptable for Bethesda III and IV nodules. However, if thyroidectomy is preferred for clinical reasons, gene expression profiles are unnecessary. Instead, comprehensive DNA tumor profiling that can guide treatment should be performed on the resected tissue. The AAES also points out the importance of knowledge of institutional malignancy rates.⁵³

Reports on second generation molecular tests for assessing indeterminate thyroid nodules in general show improved performance with increased sensitivity and specificity over their predecessors and may be considered “general” tests with the ability to both rule-out the need for surgery if negative and rule-in the extent of treatment if positive. However, the prevalence of variants in RAS genes in benign nodules suggests the need for caution in decision making. Relying on the presence of a single RAS mutation to drive clinical decision making may result in unnecessary treatment. Additional factors such as biological behavior of the nodule, secondary variants and other clinical indications should be considered in nodules positive for RAS variants.

Given the cost and risks associated with thyroid surgery, the clinical decision making that goes into the extent of surgery, additional follow up management, and published guidelines, this contractor finds that molecular tests that aid in medical decision making for thyroid nodules of Bethesda Categories III-V are reasonable and necessary. Specifically, this contractor recognizes improved outcomes by safely precluding unnecessary surgical procedures with these services as well as better selecting patients who may benefit from such procedures. Reference to specific tests in this document does not imply coverage by this contractor.

N/A

N/A

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts: Thyroid Cancer. Accessed 6/26/2023. https://seer.cancer.gov/statfacts/html/thyro.html
2. Chen DW, Yeh MW. Disparities in thyroid care. Endocrinol Metab Clin North Am. 2022;51(2):229-241. doi:10.1016/j.ecl.2021.11.017
3. Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer.2020;126(10):2225-2249. doi:10.1002/cncr.32802
4. Lorusso L, Cappagli V, Valerio L, et al. Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities. Int J Mol Sci. 2021;22(6):3117. doi:10.3390/ijms22063117
5. Chernock RD, Hagemann IS. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. Am J Clin Pathol. 2015;143(6):768-777. doi:10.1309/AJCPHWACTTUYJ7DD
6. Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644-660. doi:10.1038/nrendo.2017.76
7. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322. doi:10.1001/jamaoto.2014.1
8. Hoang JK, Nguyen XV, Davies L. Overdiagnosis of thyroid cancer: answers to five key questions. Acad Radiol. 2015;22(8):1024-1029. doi:10.1016/j.acra.2015.01.019
9. Kitahara CM, Sosa JA. Understanding the ever-changing incidence of thyroid cancer. Nat Rev Endocrinol. 2020;16(11):617-618. doi:10.1038/s41574-020-00414-9
10. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-1348. doi:10.1001/jama.2017.2719
11. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614-617. doi:10.1056/NEJMp1604412
12. Lee M, Powers AE, Morris LGT, Marti JL. Reversal in thyroid cancer incidence trends in the United States, 2000-2017. Thyroid. 2020;30(8):1226-1227. doi:10.1089/thy.2020.0321
13. Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000-2018. Thyroid. 2022;32(5):560-570. doi:10.1089/thy.2021.0662
14. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023-1029. doi:10.1001/jamaoncol.2016.0386
15. Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association guidelines on the management of thyroid nodules and differentiated Thyroid Cancer Task Force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27(4):481-483. doi:10.1089/thy.2016.0628
16. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid ancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020
17. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol. 2017;14(5):587-595. doi:10.1016/j.jacr.2017.01.046
18. Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995-2015). J Natl Cancer Inst. 2020;112(8):810-817. doi:10.1093/jnci/djz202
19. Ginzberg SP, Soegaard Ballester JM, Wirtalla CJ, et al. Insurance-based disparities in guideline-concordant thyroid cancer care in the era of de-escalation. J Surg Res. 2023;289:211-219. doi:10.1016/j.jss.2023.03.046
20. Radhakrishnan A, Reyes-Gastelum D, Abrahamse P, et al. Physician specialties involved in thyroid cancer diagnosis and treatment: implications for improving health care disparities. J Clin Endocrinol Metab. 2022;107(3):e1096-e1105. doi:10.1210/clinem/dgab781
21. Ginzberg SP, Soegaard Ballester JM, Wirtalla CJ, et al. Racial and ethnic disparities in appropriate thyroid cancer treatment, before and after the release of the 2015 American Thyroid Association Guidelines. Ann Surg Oncol. 2023;30(5):2928-2937. doi:10.1245/s10434-023-13158-3
22. White C, Weinstein MC, Fingeret AL, et al. Is less more? A microsimulation model comparing cost-effectiveness of the revised American Thyroid Association's 2015 to 2009 Guidelines for the management of patients with thyroid nodules and differentiated thyroid Cancer. Ann Surg. 2020;271(4):765-773. doi:10.1097/SLA.0000000000003074
23. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341-1346. doi:10.1089/thy.2017.0500
24. Padmanabhan V, Marshall CB, Akdas Barkan G, et al. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the Bethesda system for reporting thyroid cytology when reviewing slides from different institutions: a study of interobserver variability among cytopathologists. Diagn Cytopathol. 2017;45(5):399-405. doi:10.1002/dc.23681
25. Kuzan TY, Guzelbey B, Turan Guzel N, Kuzan BN, Cakir MS, Canbey C. Analysis of intra-observer and inter-observer variability of pathologists for non-benign thyroid fine needle aspiration cytology according to Bethesda System categories. Diagn Cytopathol. 2021;49(7):850-855. doi:10.1002/dc.24756
26. Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. J Clin Endocrinol Metab. 2017;102(7):2543-2551. doi:10.1210/jc.2017-00255
27. National Comprehensive Cancer Network. Thyroid Carcinoma (Version 2.2023). Accessed 6/26/2023. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
28. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 23 2012;367(8):705-715. doi:10.1056/NEJMoa1203208
29. Borowczyk M, Szczepanek-Parulska E, Olejarz M, et al. Evaluation of 167 gene expression classifier (GEC) and ThyroSeq v2 diagnostic accuracy in the preoperative assessment of indeterminate thyroid nodules: bivariate/HROC meta-analysis. Endocr Pathol. 2019;30(1):8-15. doi:10.1007/s12022-018-9560-5
30. Silaghi CA, Lozovanu V, Georgescu CE, et al. Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis. Front Endocrinol(Lausanne).2021;12:649522. doi:10.3389/fendo.2021.649522
31. Vargas-Salas S, Martinez JR, Urra S, et al. Genetic testing for indeterminate thyroid cytology: review and meta-analysis. Endocr Relat Cancer.2018;25(3):R163-R177. doi:10.1530/ERC-17-0405
32. Al-Qurayshi Z, Deniwar A, Thethi T, et al. Association of malignancy prevalence with test properties and performance of the gene expression classifier in indeterminate thyroid nodules. JAMA Otolaryngol Head Neck Surg. 2017;143(4):403-408. doi:10.1001/jamaoto.2016.3526
33. Marti JL, Avadhani V, Donatelli LA, et al. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid Nodules. Ann Surg Oncol. 2015;22(12):3996-4001. doi:10.1245/s10434-015-4486-3
34. Valderrabano P, Hallanger-Johnson JE, Thapa R, Wang X, McIver B. Comparison of postmarketing findings vs the initial clinical validation findings of a thyroid nodule gene expression classifier: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2019;145(9):783-792. doi:10.1001/jamaoto.2019.1449
35. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-3397. doi:10.1210/jc.2011-1469
36. Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120(23):3627-3634. doi:10.1002/cncr.29038
37. Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid. 2015;25(11):1217-1223. doi:10.1089/thy.2015.0305
38. Marcadis AR, Valderrabano P, Ho AS, et al. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules. Surgery. 2019;165(1):17-24. doi:10.1016/j.surg.2018.04.062
39. Taye A, Gurciullo D, Miles BA, et al. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Surgery. 2018;163(1):97-103. doi:10.1016/j.surg.2017.07.032
40. Valderrabano P, Khazai L, Leon ME, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer. 2017;24(3):127-136. doi:10.1530/ERC-16-0512
41. Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 2018;153(9):817-824. doi:10.1001/jamasurg.2018.1153
42. Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer. 15 2018;124(8):1682-1690. doi:10.1002/cncr.31245
43. Lee E, Terhaar S, McDaniel L, et al. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: a systematic review and meta-analysis. Am J Otolaryngol. 2022;43(3):103394. doi:10.1016/j.amjoto.2022.103394
44. Patel J, Klopper J, Cottrill EE. Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities. Front Endocrinol(Lausanne).2023;14:1101410. doi:10.3389/fendo.2023.1101410
45. Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol. 2021;7(1):70-77. doi:10.1001/jamaoncol.2020.5935
46. Kim NE, Raghunathan RS, Hughes EG, et al. Bethesda III and IV thyroid nodules managed nonoperatively after molecular testing with Afirma GSC or Thyroseq v3. J Clin Endocrinol Metab. 2023; dgad181. doi:10.1210/clinem/dgad181
47. Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2021;36(3):514-524. doi:10.3803/EnM.2021.1082
48. Tao Y, Wang F, Shen X, et al. BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer. J Clin Endocrinol Metab. 2021;106(11):3228-3238.
49. Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610.
50. Yip L. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol. 2015;111(1):43-50.
51. Najafian A, Noureldine S, Azar F, et al. RAS Mutations, and RET/PTC and PAX8/PPAR-gamma chromosomal rearrangements are also prevalent in benign thyroid lesions: implications thereof and a systematic review. Thyroid. 2017;27(1):39-48.
52. Guan H, Toraldo G,. Thyroid. 2020;30(4):536-547.
53. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Ann Surg. 2020;271(3):e21-e93.

• Other (LCD Request from Laboratory)

• Thyroid Nodules
• Risk Stratification